Alnylam Pharmaceuticals reported third‑quarter 2025 results with total revenues of $1.25 billion, including $851 million in net product revenues, a 149 % year‑over‑year increase. Net income rose to $251 million from a $112 million loss in the same quarter of 2024, which had total revenues of $500.9 million.
The TTR franchise generated $724 million, driven by Amvuttra sales of $685 million, up 165 % from the prior year, while Onpattro revenue fell 22 % to $39 million as patients switched to the new therapy. The rare‑disease franchise produced $127 million, with Givlaari at $74 million and Oxlumo at $53 million.
Alnylam raised fiscal 2025 sales guidance to $3.6 billion–$3.8 billion, up from $3.3 billion–$3.55 billion, and lifted its TTR franchise guidance to $2.48 billion–$2.53 billion. The rare‑disease franchise guidance was increased to $475 million–$525 million. Management cited strong uptake of Amvuttra, its quarterly dosing schedule, and broad payer coverage as key drivers of the guidance revision.
The company received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts seeking documents on fee and discount arrangements for its four products; Alnylam stated the investigation does not affect its financial results. Cash, cash equivalents, and marketable securities stood at $2.7 billion, and the company issued convertible senior notes and entered a revolving credit facility to strengthen its balance sheet. In the pipeline, Alnylam secured a $300 million milestone payment from Roche for the ZENITH trial of zilebesiran and launched new Phase 3 studies for nucresiran and other candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.